Maxim Group analyst Jason McCarthy maintained a Buy rating on Atossa Genetics (NASDAQ: ATOS) today and set a price target of $10. The company’s shares opened today at $3, close to its 52-week low of $2.30.
McCarthy noted:
“Atossa announced that the P1 study of topical endoxifen in men (healthy subjects, N=24) has completed dosing and clinical visits. Data is expected in 3Q18 which should set the stage to move into a P2 program in gynecomastia (male breast enlargement).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 9.4% and a 40.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
Atossa Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $10.
See today’s analyst top recommended stocks >>
Based on Atossa Genetics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $1.87 million. In comparison, last year the company had a GAAP net loss of $1.7 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Atossa Genetics, Inc. operates as a clinical-stage pharmaceutical company, which focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. It offers ForeCYTE and ArgusCYTE diagnostic tests.
Read More on ATOS:
